Patents by Inventor Andrew Terrance METCALF

Andrew Terrance METCALF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGFR3 inhibitor compounds
    Patent number: 11878976
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: January 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
  • Compounds for the treatment of BRAF-associated diseases and disorders
    Patent number: 11634409
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 25, 2023
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • FGFR3 INHIBITOR COMPOUNDS
    Publication number: 20230095122
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Application
    Filed: March 3, 2022
    Publication date: March 30, 2023
    Inventors: Adedoyin David ABRAHAM, Desta Doro BUME, Kevin Ronald CONDROSKI, Robert Alan HAZLITT, Timothy Scott KERCHER, Andrew Terrance METCALF, Kaveri Balan URKALAN, Shane Michael WALLS, Andrew Karl DILGER
  • COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
    Publication number: 20220289721
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 15, 2022
    Applicant: Array BioPharma Inc.
    Inventors: Patrick Michael BARBOUR, Katie Keaton BROWN, Adam Wade COOK, Erik James HICKEN, Dean Russell KAHN, Ellen Ruth LAIRD, Andrew Terrance METCALF, David Austin MORENO, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Brett Joseph PRIGARO, Li REN, Eugene TARLTON
  • Compounds for the treatment of BRAF-associated diseases and disorders
    Patent number: 11414404
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 16, 2022
    Assignee: Array BioPharma Inc.
    Inventors: Patrick Michael Barbour, Katie Keaton Brown, Adam Wade Cook, Erik James Hicken, Dean Russell Kahn, Ellen Ruth Laird, Andrew Terrance Metcalf, David Austin Moreno, Bradley Jon Newhouse, Spencer Phillip Pajk, Brett Joseph Prigaro, Li Ren, Eugene Tarlton
  • COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS
    Publication number: 20200407344
    Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.
    Type: Application
    Filed: June 24, 2020
    Publication date: December 31, 2020
    Applicant: Array BioPharma Inc.
    Inventors: Patrick Michael BARBOUR, Katie Keaton BROWN, Adam Wade COOK, Erik James HICKEN, Dean Russell KAHN, Ellen Ruth LAIRD, Andrew Terrance METCALF, David Austin MORENO, Bradley Jon NEWHOUSE, Spencer Phillip PAJK, Brett Joseph PRIGARO, Li REN, Eugene TARLTON